RT Journal Article
SR Electronic
T1 A Genes & Health pilot recall study of intrahepatic cholestasis of pregnancy and cholestatic liver disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.10.18.24314654
DO 10.1101/2024.10.18.24314654
A1 Constantinides, Maria
A1 Gafton, Joseph
A1 Garcia, Ana Cristina Angel
A1 Genes and Health
A1 Dixon, Peter H.
A1 Williamson, Catherine
A1 Linton, Kenneth
A1 Finer, Sarah
A1 Gill, Upkar S.
A1 Zöllner, Julia
YR 2024
UL http://medrxiv.org/content/early/2024/10/18/2024.10.18.24314654.abstract
AB Background Cholestatic liver disease disproportionately affects South Asians, yet they remain underrepresented in genomic studies. This recall study aimed to recall volunteers from a British South Asian genetic cohort that were considered to be at high risk of cholestatic liver disease based on their genotype or phenotype.Methods Cases were defined as participants with rare (minor allele frequency <1%) heterozygous loss of function (LoF) variants in ABCB4 and ABCB11 (genotype re-call) or with a previous intrahepatic cholestasis of pregnancy (ICP) diagnosis (ICD10 O26.6). Cases were matched 1:1 to controls. A detailed medical and family history was taken along with fasting anthropometric and transient elastography (TE) measurements and blood samples.Results Out of 22 eligible volunteers, 9 (41%) participated in the recall (8/9 genotype and 1/9 phenotype recall). Among the cases there were 5 ABCB4 LoF, 3 ABCB11 LoF, and 1 ICP phenotype. Of these, 6/9 (66.7%) were newly identified with a cholestatic phenotype (genotype re-call). Specifically, 3/6 (50%) had increased liver stiffness on TE with one also demonstrating abnormal liver blood tests. 2/6 (33.3%) experienced at least 2 cholestatic symptoms and an additional 1/6 (16.7%) demonstrated abnormal liver blood tests without increased liver stiffness.Conclusion This pilot study demonstrated new evidence of cholestatic liver disease in 66.7% of volunteers, underscoring the potential of rare heterozygous ABCB4/11 variants as markers for identifying individuals at high risk of developing cholestatic liver disease. Consequently, individuals at higher genetic risk benefit from monitoring, personalised treatment and prevention strategies for cholestatic liver disease.Plain language summary We aimed to identify British South Asians at high risk of liver disease due to specific genetic factors, such as issues with bile production or liver problems during pregnancy. We invited these individuals to a clinic, where we collected their medical and family history, conducted liver blood tests, and performed a scan to check for early signs of liver scarring. We found that nearly two out of three participants had undetected liver disease. This finding suggests that genetic factors are linked to developing liver disease, highlighting the importance of early detection and monitoring for those at risk.Competing Interest StatementSF receives research funding for Genes & Health from MRC, NIHR, Alnylam Pharmaceuticals, Takeda, Glaxo Smith Kline, Merck, Pfzer, NovoNordisk, Maze Pharmaceuticals, Bristol Myers Squibb.CW consults for Mirum and GSK.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Genes & Health ethical approval was granted by the South East London National Research Ethics Committee (14/LO/1240) in 2014. This recall study operated with ethical approval from the West of Scotland Research Ethics Service (22/WS/0109). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes